FDA approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA approved Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection. Gilead told BioCentury it plans to launch the drug this

Read the full 246 word article

User Sign In